The Rs243865 Polymorphism Increases the Risk of Prostate Cancer: A Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Oct 27

PMID 29069837

Citations 3

Authors

Kun Liu

Shuo Gu

Xuzhong Liu

Qing Sun

Yunyan Wang

Junsong Meng

Zongyuan Xu

Affiliations

Soon will be listed here.

Abstract

Ct, Or: 1.80, 95% CI: 1.34-2.42, < 0.001; C vs.

T, Or: 1.32, 95% CI: 1.05-1.66, = 0.016, respectively). However, there was no significant difference between the co-recessive model and recessive model. Our meta-analysis results suggest that rs243865 polymorphisms are significantly associated with higher risk of prostate cancer.

Citing Articles

Current evidence on the relationships among five polymorphisms in the matrix metalloproteinases genes and prostate cancer risk.

Gui J, Zhou H, Li S, Chen A, Liu Q, Zhu L Sci Rep. 2024; 14(1):11355.

PMID: 38762659 PMC: 11102503. DOI: 10.1038/s41598-024-62016-z.

CORRELATION OF EXPRESSION OF TGF- β AND MMP2 BETWEEN PROSTATIC ADENOCARCINOMA AND ADJACENT UNAFFECTED PARENCHYMA.

Masic S, Bacalja J, Vucic M, cupic H, Tomas D, Ulamec M Acta Clin Croat. 2023; 61(Suppl 3):9-14.

PMID: 36938549 PMC: 10022412. DOI: 10.20471/acc.2022.61.s3.1.

Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: a meta-analysis and systematic review.

Zhou H, Zhu X Cancer Manag Res. 2018; 10:5247-5259.

PMID: 30464622 PMC: 6223342. DOI: 10.2147/CMAR.S177551.

References

Biondi-Zoccai G, Lotrionte M, Landoni G, Modena M . The rough guide to systematic reviews and meta-analyses. HSR Proc Intensive Care Cardiovasc Anesth. 2013; 3(3):161-73. PMC: 3484632. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Turner J, Crossley M . Mammalian Krüppel-like transcription factors: more than just a pretty finger. Trends Biochem Sci. 1999; 24(6):236-40. DOI: 10.1016/s0968-0004(99)01406-1. View

Price S, Greaves D, Watkins H . Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2000; 276(10):7549-58. DOI: 10.1074/jbc.M010242200. View

Qi F, Liu X, Wu H, Yu X, Wei C, Huang X . Long noncoding AGAP2-AS1 is activated by SP1 and promotes cell proliferation and invasion in gastric cancer. J Hematol Oncol. 2017; 10(1):48. PMC: 5314629. DOI: 10.1186/s13045-017-0420-4. View

Adabi Z, Mohsen Ziaei S, Imani M, Samzadeh M, Narouie B, Jamaldini S . Genetic Polymorphism of MMP2 Gene and Susceptibility to Prostate Cancer. Arch Med Res. 2015; 46(7):546-50. DOI: 10.1016/j.arcmed.2015.08.004. View

Jeong C, Hong S, Byun S, Jeon S, Seo S, Lee H . Selection Criteria for Active Surveillance of Patients with Prostate Cancer in Korea: A Multicenter Analysis of Pathology after Radical Prostatectomy. Cancer Res Treat. 2017; 50(1):265-274. PMC: 5784641. DOI: 10.4143/crt.2016.477. View

Xu W, Xu H, Fang M, Wu X, Xu Y . MKL1 links epigenetic activation of MMP2 to ovarian cancer cell migration and invasion. Biochem Biophys Res Commun. 2017; 487(3):500-508. DOI: 10.1016/j.bbrc.2017.04.006. View

Qin H, Sun Y, Benveniste E . The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem. 1999; 274(41):29130-7. DOI: 10.1074/jbc.274.41.29130. View

10.

Curran S, Murray G . Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999; 189(3):300-8. DOI: 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C. View

11.

Meyer T, Chu L, Li Q, Yu K, Rosenberg P, Menashe I . The association between inflammation-related genes and serum androgen levels in men: the prostate, lung, colorectal, and ovarian study. Prostate. 2011; 72(1):65-71. PMC: 3156884. DOI: 10.1002/pros.21407. View

12.

Ye H, He Y, Wang J, Song T, Lan Z, Zhao Y . Effect of matrix metalloproteinase promoter polymorphisms on endometriosis and adenomyosis risk: evidence from a meta-analysis. J Genet. 2016; 95(3):611-9. DOI: 10.1007/s12041-016-0675-5. View

13.

Ghosh A, Dasgupta D, Ghosh A, Roychoudhury S, Kumar D, Gorain M . MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis. 2017; 8(3):e2706. PMC: 5386529. DOI: 10.1038/cddis.2017.123. View

14.

Srivastava P, Lone T, Kapoor R, Mittal R . Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Arch Med Res. 2012; 43(2):117-24. DOI: 10.1016/j.arcmed.2012.02.006. View

15.

Jacobs E, Hsing A, Bain E, Stevens V, Wang Y, Chen J . Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17(4):972-7. DOI: 10.1158/1055-9965.EPI-07-2787. View

16.

Ding X, Yang D, Xia L, Chen B, Yu S, Niu Y . Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating macrophages with alteration of the TIMP-1/MMP2/MMP9 signals. Mol Cancer. 2015; 14:16. PMC: 4316804. DOI: 10.1186/s12943-014-0281-1. View

17.

Lu S, Zhu Q, Zhang Y, Song W, Wilson M, Liu P . Dual-Functions of miR-373 and miR-520c by Differently Regulating the Activities of MMP2 and MMP9. J Cell Physiol. 2014; 230(8):1862-70. DOI: 10.1002/jcp.24914. View

18.

Reis S, Pontes Jr J, Villanova F, Borra P, Antunes A, DallOglio M . Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. J Urol. 2009; 181(5):2320-5. DOI: 10.1016/j.juro.2009.01.012. View

19.

Haque S, Akhter N, Lohani M, Ali A, Mandal R . Matrix metalloproteinase-2 -1306 C>T gene polymorphism is associated with reduced risk of cancer: a meta-analysis. Asian Pac J Cancer Prev. 2015; 16(3):889-96. DOI: 10.7314/apjcp.2015.16.3.889. View

20.

Ozturk H, Karapolat I . F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer. Oncol Lett. 2016; 11(1):316-322. PMC: 4727044. DOI: 10.3892/ol.2015.3903. View